Uromigos-Paper of the Month
Advertisement
Karim Fizazi, MD, PhD, joins the show to discuss the phase III TALAPRO-2 trial published in Nature.
Dr. Rahul Aggarwal discusses his recent paper on a phase 1/2 study on Lu-177 with pembrolizumab for mCRPC.
Dr. Susan F. Slovin discusses her recent paper that examined abiraterone with and without cabazitaxel for mCRPC.
Dr. Meeks discusses expression-based subtypes for defining pathologic response to neoadjuvant ICIs in patients with MIBC.
Dr. Andrea Necchi describes his recent phase 2 study on the use of neoadjuvant pembrolizumab and nab-paclitaxel for MIBC.
The Uromigos chat with Axel Merseburger about his paper on continuing enzalutamide with docetaxel for the treatment of CRPC.
The Uromigos chat with Cora Sternberg on her paper on FGFR inhibition in advanced urothelial cancer.
John Kelly summarizes a recent paper published in JAMA that describes the benefits of robotic surgery versus open cystectomy.
Alex Wyatt joins The Uromigos to answer questions about ctDNA in prostate cancer and discuss his latest paper on that topic.
Syed Hussain and Sam Funt describe their studies on this topic.
Martin Stockler describes the ENZAMET trial, which shows mixed effects of enza on QOL in prostate cancer.
Yelena Janjigian describes ipi/nivo versus nivo chemo versus chemo in gastric cancer.
Elizabeth de Vries describes her paper on this topic published in Annals of Oncology.
Chad Tang discusses his oncology paper recently published in Lancet.
Dr. Samra Turajlic describes her paper on clear cell renal cell carcinoma.
Dr. Mike Atkins discusses the role of CTLA4 inhibition in RCC.
Dr. Tanya Dorff discusses the TALAPRO-1 study and the role of PARP inhibitors in prostate cancer.
Martin Eklund discusses his papers published in the New England Journal of Medicine and Lancet Oncology.
Dr. Eric Jonasch gives an overview of his paper published in Nature Medicine.
Dr. Petros Grivas discusses the accelerated approval of sacituzumab govitecan in bladder cancer.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.